This month, four companies are poised to announce share buybacks, with Aurobindo Pharma leading the way. The company has approved a buyback worth ₹800 crore (approximately $96 million USD) at a price of ₹1,475 per share, a 10% premium over its previous closing price of ₹1,339.80 on the National Stock Exchange (NSE). Wipro will consider its buyback proposal alongside its financial results on April 16, marking its fifth buyback since its last in 2020. Windlas Biotech will also discuss its first-ever buyback on April 17, while Cyient's board will meet on April 23 to consider its own buyback proposal. Recent tax changes under the Finance Bill 2026 impose a 12% surcharge on capital gains from share buybacks, specifically affecting promoters, while non-promoter shareholders remain under normal provisions.